GSK buys respiratory drug maker Aiolos in $1.4bn deal
GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).
Source: Sharecast
The deal provides GSK with access to Aiolos' AIO-001, a drug ready to enter phase II clinical development for the treatment of adult patients with asthma, with potential for additional indications including chronic rhinosinusitis with nasal polyps.
GSK will pay $1bn upfront, with an extra $400m in milestone payments if targets are met.
Founded in 2023, Aiolos Bio is a San Francisco, USA and London, UK-based clinical-stage, private, biopharmaceutical company focused on treating respiratory disease.
Whether you're looking for a Share Dealing Account, Stocks and Shares ISA or a Self-Invested
Personal Pension (SIPP), we've got an account to suit your needs.
IWeb is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
